



Press release 2015-07-29

## Skandion Clinic reconfirms C-RAD procurement

The Skandion Clinic (Skandionkliniken) in Uppsala, Sweden has reconfirmed its previous decision to equip its proton therapy center with the C-RAD surface tracking solution. This second public tender was decided in C-RAD's favor. The tender includes systems for four rooms in total with an option for two additional rooms and a long-term service contract.

An appeal has been filed in the second iteration of this tender, however, by the same competitor that had filed an appeal in the first round: Radiotherapy Equipment Scandinavia AB (Radeq), which distributes a competitive product. The case is pending with the responsible court. The timeframe for a court decision is open.

### *About C-RAD*

*C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 37. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit [www.c-rad.com](http://www.c-rad.com).*

### **For further information:**

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email [investors@c-rad.com](mailto:investors@c-rad.com)

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).